Head-To-Head Analysis: ImageneBio (NASDAQ:IMA) vs. Tango Therapeutics (NASDAQ:TNGX)

Tango Therapeutics (NASDAQ:TNGX – Get Free Report) and ImageneBio (NASDAQ:IMA – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Profitability

This table compares Tango Therapeutics and ImageneBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Tango Therapeutics N/A -30.34% -28.28%
ImageneBio N/A -32.90% -29.66%

Valuation & Earnings

This table compares Tango Therapeutics and ImageneBio”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Tango Therapeutics N/A N/A -$101.59 million ($1.37) -18.61
ImageneBio N/A N/A -$45.35 million ($4.58) -0.76

Tango Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 2.2% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Tango Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, ImageneBio has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Tango Therapeutics and ImageneBio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tango Therapeutics 2 2 13 0 2.65
ImageneBio 2 0 1 0 1.67

Tango Therapeutics presently has a consensus price target of $45.54, suggesting a potential upside of 78.58%. ImageneBio has a consensus price target of $28.00, suggesting a potential upside of 706.92%. Given ImageneBio’s higher possible upside, analysts clearly believe ImageneBio is more favorable than Tango Therapeutics.

Summary

Tango Therapeutics beats ImageneBio on 8 of the 11 factors compared between the two stocks.

About Tango Therapeutics

(Get Free Report)

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.

About ImageneBio

(Get Free Report)

ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Its research and development pipeline includes investigational medicines at various stages of clinical development; the company does not yet have marketed products. Key programs include IMG-007, an investigational antibody targeting OX40 being studied for atopic dermatitis and other inflammatory conditions, and IMG-004, an oral investigational BTK inhibitor for immune-mediated diseases.

Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.